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A Two-pronged Binding Mechanism of IgG to
the Neonatal Fc Receptor Controls Complex
Stability and IgG Serum Half-life*□S
Pernille Foged Jensen‡, Angela Schoch§, Vincent Larraillet¶, Maximiliane Hilger¶,
Tilman Schlothauer¶, Thomas Emrich§, and Kasper Dyrberg Rand‡
The success of recombinant monoclonal immunoglobu-
lins (IgG) is rooted in their ability to target distinct antigens
with high affinity combined with an extraordinarily long
serum half-life, typically around 3 weeks. The pharmaco-
kinetics of IgGs is intimately linked to the recycling mech-
anism of the neonatal Fc receptor (FcRn). For long serum
half-life of therapeutic IgGs, the highly pH-dependent in-
teraction with FcRn needs to be balanced to allow effi-
cient FcRn binding and release at slightly acidic pH and
physiological pH, respectively. Some IgGs, like the anti-
body briakinumab has an unusually short half-life of 8
days. Here we dissect the molecular origins of excessive
FcRn binding in therapeutic IgGs using a combination of
hydrogen/deuterium exchange mass spectrometry and
FcRn affinity chromatography. We provide experimental
evidence for a two-pronged IgG-FcRn binding mechanism
involving direct FcRn interactions with both the Fc region
and the Fab regions of briakinumab, and correlate the
occurrence of excessive FcRn binding to an unusually
strong Fab-FcRn interaction. Molecular & Cellular Pro-
teomics 16: 10.1074/mcp.M116.064675, 451–456, 2017.
The interaction between the neonatal Fc receptor (FcRn)1
and IgG is of high importance for effective humoral immunity
and of considerable pharmaceutical interest because of its
role in regulating IgG pharmacokinetics (1). FcRn binds anti-
bodies in a strict pH-dependent manner with high binding
affinity at mild acidic conditions (pH 6.0) and no measurable
affinity at physiological pH (pH 7.4). This characteristic pH
dependence is crucial for FcRn mediated IgG recycling. In the
vascular endothelium FcRn binds IgG in the slightly acidic
environment of the endosomes and release IgG to the blood
stream at physiological pH thereby circumventing lysosomal
degradation of IgG and leading to the extraordinary long
half-life of most antibodies of 21 days (2).
Human IgGs consist of two antigen binding Fab regions and
a Fc region involved in Fc receptor interactions. FcRn binds to
the CH2-CH3 regions of the Fc domain of IgG (3, 4). However,
several studies showing differential FcRn binding of recombi-
nant IgGs with identical Fc regions (5, 6) suggest that the
interaction could be influenced by the Fab regions. Schlo-
thauer et al. (6) recently demonstrated that intact antibodies
can dissociate from FcRn at different pH values than their
corresponding Fc fragments strongly suggesting a contribu-
tion of the antibody Fab in FcRn binding. However, the role of
the Fab regions in FcRn binding is still a matter of discussion
in the literature (7–12) and the molecular mechanism is not
clear. Limited structural information is available for the com-
plex of full-length IgG and FcRn and much of our knowledge
of the binding interface comes from X-ray crystal structures of
only the Fc region bound to FcRn (3, 4).
We recently applied a method based on hydrogen/deute-
rium exchange mass spectrometry (HDX-MS) to detect local
structural conformation and dynamics of IgG and FcRn upon
interaction (13). HDX-MS monitors the isotopic exchange of
hydrogen and deuterium of proteins in solution and reports on
the protection of amide hydrogens from intra- and intermo-
lecular hydrogen bonds and to a lesser extent solvent acces-
sibility (14, 15). Our studies (13) revealed structural stabiliza-
tion of the Fab regions upon FcRn interaction, which could be
caused by a conformational link between the Fc and Fab
regions or by direct interaction with FcRn.
Here, we perform HDX-MS analyses of a unique set of
antibodies with different FcRn binding characteristics to dis-
sect the conformational origins of the involvement of Fab in
FcRn binding. The antibodies ustekinumab (Stelara) and bri-
akinumab (Ozespa) targeting the p40 subunit of IL-12 and
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IL-23 show remarkable differences in terminal half-life with
about 20 days for the former and only 8–9 days for the latter
(16). Recent studies by Schoch et al. (17) indicates this differ-
ence in the elimination phase is FcRn-mediated as briaki-
numab showed excessive FcRn binding mediated by posi-
tively charged amino acids in the variable domain. While the
antibodies had similar binding affinity at pH 5.5 (17), they
showed large differences in FcRn dissociation pH when ana-
lyzed by FcRn affinity chromatography (17) (described in de-
tail in (6)). Ustekinumab dissociated at a pH of7.45 whereas
the dissociation pH of briakinumab was 7.85. Mutation of
three residues in the light chain (LC) complementarity deter-
mining region (CDR) of briakinumab (R27A, R57A and R97A)
had a dramatic impact in dissociation pH changing the elution
pH to 7.5. Interestingly, the isolated Fc fragments of the
antibodies showed identical FcRn dissociation at a pH of
about 7.45 (17) indicating a clear role of the briakinumab Fab
region in differential FcRn dissociation of the intact IgGs.
EXPERIMENTAL PROCEDURES
Expression and Purification of Monoclonal Antibodies and FcRn—
The recombinant human monoclonal IgG1 antibodies ustekinumab
(CNTO 1275, Stelara, CAS Registry Number 815610-63-0), briaki-
numab (ABT 874, J 695, Ozespa, SEQ ID NO 36, PNWO2001014162-
A2) and a briakinumab variant (R27A, R57A and R97A) were ex-
pressed and purified as described previously (17) and buffered in 50
mM Na phosphate, 50 mM NaCl, pH 6.5 (Roche Diagnostics, Penz-
berg, Germany). Recombinant human FcRn was expressed in
HEK293F cells and purified as described previously (6) and buffered
in 50 mM Na phosphate, 50 mM NaCl, pH 6.5 (Roche Diagnostics,
Penzberg, Germany).
Hydrogen/Deuterium Exchange Mass Spectrometry—The antibod-
ies ustekinumab, briakinumab and the briakinumab variant (72 pmol/
l) and FcRn (165 pmol/l) were mixed and diluted in 99.9% D2O 50
mM Na phosphate, 50 mM NaCl, pH 6.5 to a final D2O content of 90%
and an Ab and FcRn concentration of 1.2 pmol/l and 8.5 pmol/l,
respectively. Hydrogen exchange was performed at 22 °C for various
time points from 15 s up to 5 h. Fully deuterated samples were
prepared by overnight incubation in 6 M deuterated Gnd-HCl at a final
D2O content of 90%. Hydrogen exchange was quenched by a 1:1
(v/v) dilution of proteins with ice-cold 6 M Gnd-HCl, 0.5 M TCEP pH 2.3
resulting in a final pH of 2.5. The quenched samples were immediately
frozen and stored at80 °C. The samples were loaded onto a cooled
Waters NanoAcquity UPLC system (Waters Corp., Milford, MA) for
online pepsin digestion (Pierce, Rockford, IL, USA), desalting (Waters
VanGuard C18, 1.7 m, 2.1  5 mm) and reverse phase separation
(Waters BEH C18, 1.7 m, 1 100 mm) using a gradient from 8–40%
0.23% formic acid in acetonitrile (pH 2.5) in 7 min at a flow rate of 40
l/min. Mass analysis was performed with a Waters Synapt G2 HDMS
mass spectrometer using positive ion-electrospray and ion mobility.
Peptic peptides were identified in by collision induced tandem mass
spectrometry using both data dependent and -independent acquisi-
tion methods. Deuterium incorporation was determined in DynamX
ver. 3.0 (Waters Corp.). The generation of the homology model of
briakinumab is described elsewhere(17) and visualized using PyMOL
(Schro¨dinger LLC).
FcRn Affinity Chromatography—FcRn affinity columns were pre-
pared as described previously (6). For analysis of IgG-antigen com-
plexes, briakinumab and ustekinumab were bound to their target
interleukin-12 (CellSciences, Canton, MA), by mixing 0.3 nmol IgG
with 0.2 nmol IL-12. In addition, a briakinumab-IL-12 complex was
assembled using an IL-12 excess by mixing 0.3 nmol mAb with 0.8
nmol IL-12. The mAb-IL12 complexes were incubated for 30 min at
RT before FcRn affinity chromatography. The antibodies were eluted
by a linear pH gradient from pH 5.5 to 8.8 within 120 min using 20 mM
MES, 140 mM NaCl, pH 5.5 and 20 mM TRIS, 140 mM NaCl, pH 8.8 as
eluents. To determine the elution pH at particular retention times,
samples were collected every 5 min and the pH was measured offline.
RESULTS
Backbone Amide Hydrogens in the Antibody Fab Become
Protected from HDX Upon FcRn Binding—To investigate the
molecular mechanism of FcRn interaction of these antibodies,
we have performed solution phase HDX-MS experiments
of briakinumab, the briakinumab variant (R27A, R57A, and
R97A) and ustekinumab in the absence and presence of FcRn
(supplemental Fig. S1–S6). Our analyses have revealed that
several segments of the Fab regions of briakinumab and its
variant, particularly the LC CDRs, are stabilized upon FcRn
binding (Fig. 1).
The HDX of LC peptides 13–39, 48/49–73/74, 50–74, 75–
86, 88–101, and 92–101 was slowed as a result of the forma-
tion/stabilization of hydrogen bonds or/and shielding from
solvent, upon FcRn binding. Interestingly, the protected pep-
tides except peptide 75–86 correlates to the regions of the
Fab that were previously implicated in the charge dependent
interaction with FcRn (17). The difference in HDX in the un-
bound and FcRn-bound state is comparable for briakinumab
and the variant. However, as the HDX of the FcRn-bound
briakinumab variant is higher relative to that of briakinumab,
the variant is not stabilized to the same level as briakinumab
in the presence of FcRn in any of the peptides. The HDX of the
variant was increased for all peptides containing the point
mutations indicating a destabilization of hydrogen bonds in
these regions. Differences in intrinsic exchange rates (18)
because of the mutation of arginine to alanine does not cause
significant changes in deuterium incorporation that could ac-
count for the difference observed between briakinumab and
the variant (supplemental Fig. S8). We thus observe that the
conformation of the Fab of briakinumab variant is destabilized
by mutation. Furthermore, these same regions are not stabi-
lized to the same level upon FcRn binding, as for briakinumab,
in good correlation with a reduced FcRn binding of this vari-
ant. In the heavy chain (HC), peptides in the region 51–80 also
show reduced HDX upon FcRn interaction (supplemental Fig.
S1). Interestingly, previous studies (17) showed substitution of
the positively charged amino acids (K57A, K64A) in this region
impact FcRn binding negatively albeit not to the same level as
the briakinumab variant with LC substitutions (R27A, R57A,
and R97A) described here. Comparison of the deuterium con-
tent of briakinumab and ustekinumab LC peptides is not
directly possible as the LC sequence identity is only 43%
(supplemental Fig. S8) because of the different types of LCs
(lambda for briakinumab and kappa for ustekinumab). Usteki-
numab only showed reduced deuterium level upon FcRn
binding in one region (LC peptide 50–70) in the variable
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domain (supplemental Fig. S5) corresponding to our previous
results of another IgG with a kappa LC (13).
Differential HDX Protection in the CH2 Region of Briaki-
numab and Variant Upon FcRn Binding—In the antibody Fc
region the HDX-MS data revealed several regions in the anti-
body CH2 and CH3 domain that become protected from HDX
upon binding to FcRn in good overall agreement with the IgG
binding interface as revealed by X-ray crystallography of FcRn
and the Fc region of IgG (4) (supplemental Fig. S1). Several
overlapping peptides in the region 233–250 constituting a
small -helix-loop region in the CH2/CH3 domain interface
(Fig. 2) show reduced deuterium uptake when bound to FcRn
for both briakinumab and the variant which was also observed
previously for an unrelated antibody (13).
Strikingly, briakinumab showed more pronounced reduc-
tion in HDX upon FcRn binding in this region in comparison to
the variant. This suggests that FcRn binding to briakinumab
leads to an increased stabilization of this CH2 region relative
to the variant with mutations in the LC. Notably, no differences
in HDX are observed the CH2 region between unbound bri-
akinumab and the variant, indicating that the amino acid
substitution in the LC Fab alone does not result in altered
conformational dynamics in this region. The differential HDX
between briakinumab and its variant in the CH2 region is thus
not associated to structural differences in the Fc region of the
unbound states of these two antibodies. Interestingly, the
reduction in HDX in CH2 region of the briakinumab variant
(residues 241–250) upon FcRn binding is comparable to that
of ustekinumab (Fig. 2C). Both these antibodies do not display
excessive FcRn binding in contrast to briakinumab. The FcRn
affinity of all antibodies at pH 6.5 are in the very low micro-
molar range (estimated Kd from 0.3–3 M) with a measured
relative affinity normalized to the Kd of ustekinumab of 0.4 and
0.2 for the briakinumab variant and briakinumab, respectively
(17). As the labeling is performed with a large molar surplus of
FcRn, the small differences in FcRn affinity between the an-
tibodies cannot account for the observed differences in HDX
of the FcRn-bound states.
Influence of Antigen Binding on FcRn Dissociation—To in-
vestigate the role of the Fab regions on FcRn binding we
compared the FcRn interaction of unbound and IL-12 bound
ustekinumab and briakinumab by FcRn affinity chromatogra-
phy (Fig. 3).
FIG. 1. Conformational stabilization of Fab peptides revealed by HDX-MS. Homology model of briakinumab with a zoomed view of one
Fab arm with residues R27, R57 and R97 shown. In the zoomed view, regions with no difference in HDX in unbound and FcRn bound IgG are
shown in gray, regions showing reduced HDX upon FcRn binding are shown in red and regions without coverage are shown inwhite. Deuterium
uptake plots show HDX curves of briakinumab (black), briakinumab variant (red) without (bold line) and with FcRn (dashed line). Deuterium
incorporation was determined in triplicates in a time range from 15 s to 5 h labeling of unbound or FcRn-bound IgG. The fully deuterated control
of briakinumab is shown (gray star) at the last time point. **: p  0.01, *: p  0.05 indicate the level of significance between of the deuterium
uptake of IgG in the absence and presence of FcRn.
The Role of IgG Fab Region in FcRn Interaction
Molecular & Cellular Proteomics 16.3 453
Target binding of ustekinumab only had a minor effect on
FcRn dissociation as IL-12 interactions lead to a reduced
retention of approximately 2 mins in comparison to unbound
ustekinumab (peak fronting in Fig. 3A). Oppositely, briaki-
numab showed large target-mediated differences in FcRn
dissociation pH. Although unbound briakinumab shows one
late eluting peak with a retention time of approx. 93 min. (peak
3, Fig. 3B), the briakinumab-IL-12 complex assembled using
an excess of IL-12 eluted as a single peak with a markedly
reduced retention time at approx. 80 min (peak 1). The briaki-
numab-IL-12 complex assembled using an excess of briaki-
numab show three peaks with vastly different FcRn column
retention times (Fig. 3B), corresponding to unbound briaki-
numab (peak 3), briakinumab bound to one (peak 2) or two
IL-12 molecules (peak 1), respectively.
Antigen binding thus leads to a large shift in FcRn dissoci-
ation pH for briakinumab whereas the effect on ustekinumab
is minor. Antigen bound briakinumab therefore appears to
display reduced FcRn binding under elevated pH conditions
because of direct steric hindrance of either the Fab-FcRn
interaction or the Fc-FcRn interaction. The latter option does,
however, not seem plausible as antigen binding to usteki-
numab only has a minor impact on the FcRn interaction as
would not be expected if IL-12 binding shields the Fc-FcRn
interaction. Our results thus strongly support that impaired
FcRn binding of IL12-bound briakinumab is a result of a
reduced Fab-FcRn interaction, in turn, leading to a dissocia-
tion pH comparable to ustekinumab and Fc fragments (17).
DISCUSSION
So how do Fab arm mutations cause differential HDX in the
Fc region upon binding to FcRn? We propose a two-step
binding mechanism where the briakinumab Fab arms are
directly involved in FcRn binding to explain the differences in
HDX observed in the Fab and Fc region (Fig. 4).
In the two-pronged binding mechanism for briakinumab the
initial step (Step 1) is the high affinity binding of FcRn to the Fc
region (3, 4), which is followed by a direct interaction of Fab
regions with FcRn (Step 2, Fig. 4). In support of this we have
shown that cleaved Fab arms have no measurable affinity to
FcRn by SPR or FcRn chromatography (6). Thus, the Fab-
FcRn interaction requires binding of FcRn to Fc, bringing Fab
and FcRn in close spatial proximity. Our HDX-MS data shows
that the subsequent Fab-FcRn interaction in turn leads to a
more stable Fc-FcRn interaction in the 233–250 region, as we
see increased stabilization upon FcRn binding for briaki-
numab relative to the variant for which the Fab-FcRn interac-
tion (Step 2) is weakened (Fig. 1 and 2). The involvement of
direct Fab-FcRn interactions following the high affinity Fc-
FcRn binding thus leads to a more stable complex in com-
parison to IgG-FcRn complexes that do not involve strong
Fab interactions.
FIG. 2. Differential impact of FcRn binding in the Fc region (CH2) of briakinumab and its variant revealed by HDX-MS. A, Homology
model of briakinumab with zoomed view of region 241–250 (red) with the backbone amide hydrogens shown as green spheres. B, Deuterium
uptake plot for peptide 241–250 showing HDX curves of briakinumab (black), the briakinumab variant (red) without (bold) and bound to FcRn
(dashed). The fully deuterated control for briakinumab is shown (in gray star) at the last time point. **: p  0.01, *: p  0.05 indicate significance
levels comparing briakinumab and the variant when bound to FcRn. The HDX-MS experiments were performed as described in Fig. 1. C,
Difference in HDX of peptide 241–250 at the 1 h time point for briakinumab (gray), the briakinumab variant (red) and ustekinumab (blue).
FIG. 3. FcRn affinity chromatography of ustekinumab and bri-
akinumab in complex with IL-12. A, ustekinumab (dark green) and
ustekinumab-IL-12 complex with excess ustekinumab (light green). B,
briakinumab (orange), briakinumab-IL-12 complex with excess briaki-
numab (red) and with excess IL-12 (light red). Chromatographic peaks
are normalized to main peak of ustekinumab in A, and briakinumab-
IL-12 complex assembled using IL-12 excess in B. IgGs and IgG-
IL-12 complexes were loaded on the FcRn column at pH 5.5 and were
eluted with a 2 h pH gradient to pH 8.8.
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As a consequence of a strong involvement of Fab arms in
the FcRn interaction of briakinumab as opposed to usteki-
numab, we hypothesized that antigen binding (IL-12) could
have a significant effect on the FcRn binding of briakinumab
as opposed to ustekinumab. The results from FcRn chroma-
tography revealed a large impact of antigen binding that was
unique for briakinumab and not observed for ustekinumab.
These observations thus further support the proposed two-
step binding mechanism involving a direct interaction of Fc-
and subsequently Fab regions with the FcRn (Fig. 4). Interest-
ingly, it appears that both Fab arms of briakinumab can
simultaneously interact with cognate FcRn molecules bound
on each side of the Fc region as three peaks with distinct
FcRn binding are observed for the briakinumab-IL-12 com-
plex. The Fab arms of IgG molecules are inherently very
flexible in solution and the required movements for FcRn
interaction for both Fab arms is accordance with previously
measured Fab arm rotation angles and Fab-Fc and Fab-Fab
angle ranges (19). Our data clearly show how a limitation of
Fab arm mobility as a consequence of antigen binding can
limit the Fab-FcRn interaction. This may explain some of the
current discrepancies in the literature on the role of the Fab in
FcRn interaction as Fab arm mobility has been limited by
interaction with antigen or Fab specific antibodies in some of
the used in vitro assays (7, 10).
In summary, our data reveal a direct impact of the Fab
region of a therapeutic IgG on FcRn binding and significantly
expand current knowledge on a functionally important struc-
tural interplay between both the Fc and Fab regions of IgG
upon complex formation with FcRn. Based on the results
described here we conclude that the involvement of the Fab
of briakinumab in FcRn binding occurs by a direct interaction.
HDX data on the FcRn binding of another IgG1 (13) have also
shown reduced HDX in the Fab region. This strongly suggests
that the two-pronged binding mechanism of Fc and Fab to
FcRn, uncovered here for briakinumab, is an inherent property
of the IgG1 architecture and also occurs in other IgG1 mole-
cules, albeit with a varying strength of the Fab interaction as
reported in (5, 6). While the LC of briakinumab strongly influ-
ences the FcRn interaction as described here and previously
(17), a possible correlation to LC type (kappa or lambda)
needs to be investigated further. Our results demonstrate that
differences in FcRn binding of therapeutic IgGs can be be-
cause of differences in the involvement of the Fc and, in cases
such as briakinumab, the Fab regions. Evidently, the contri-
bution of both Fc and Fab regions to FcRn binding can have
significant impact on terminal half-life as observed for briaki-
numab and ultimately efficacy of therapeutic IgGs and should
be dissected and analyzed for successful development of
therapeutic IgGs with tailored pharmacokinetics.
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